Adherence with urate-lowering therapies for the treatment of gout
Arthritis Research & Therapy2009Vol. 11(2), pp. R46–R46
Citations Over TimeTop 10% of 2009 papers
Leslie R. Harrold, Susan E. Andrade, Becky A. Briesacher, Marsha A. Raebel, Hassan Fouayzi, Robert A. Yood, Ira S. Ockene
Abstract
Non-adherence amongst gout patients initiating ULDs is exceedingly common, particularly in younger patients with less comorbidity and no provider visits for gout prior to ULD initiation. Providers should be aware of the magnitude of non-adherence with ULDs.
Related Papers
- → Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients(2007)91 cited
- Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.(2012)
- → Benzbromarone Therapy in Hyperuricaemia; Comparison with Allopurinol and Probenecid(1981)14 cited
- → TREATMENT OF GOUT WITH ALTERNATE-DAY HYPO-URICAEMIC DRUGS(1978)4 cited
- Biochemical effectiveness of allopurinol monotherapy and allopurinol-probenecid combination therapy in previously benzbromarone-treated gout patients